latest update:
[TrialBase DB]

trial summary · NCT07194980

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Safety and Efficacy of the Addition of Nemtabrutinib to Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by Fred Hutchinson Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07194980phase PHASE2enrollment 20start 2026-12-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase II trial studies how well the addition of nemtabrutinib to lisocabtagene maraleucel in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Nemtabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lisocabtagene maraleucel is a type of treatment called chimeric antigen receptor (CAR) T-cell therapy, in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T-cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T-cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T-cells are grown in the laboratory and given to the patient by infusion for treatment. Adding nemtabrutinib to lisocabtagene maraleucel may be an effective treatment for relapsed/refractory CLL/SLL.

Source record: https://clinicaltrials.gov/study/NCT07194980

Facts

registry idNCT07194980
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
sponsorFred Hutchinson Cancer Center
sponsor classOTHER
enrollment20
start date2026-12-01
primary completion2029-10-20
completion2029-10-20
results postednot reported

Conditions

  • Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

  • Nemtabrutinib
  • Lisocabtagene Maraleucel

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG

Work with this record